Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

被引：0
|
作者：
K. H. Chan
R. L. O’Connell
D. R. Sullivan
L. S. Hoffmann
K. Rajamani
M. Whiting
M. W. Donoghoe
M. Vanhala
A. Hamer
B. Yu
R. Stocker
M. K. C. Ng
A. C. Keech
机构：
[1] Royal Prince Alfred Hospital,Department of Cardiology
[2] Sydney Medical School,National Health and Medical Research Council Clinical Trials Centre, Level 6, Medical Foundation Building, K25
[3] The Heart Research Institute,Department of Biochemistry
[4] University of Sydney,Center for Vascular Research, School of Medical Sciences (Pathology) and Bosch Institute
[5] Royal Prince Alfred Hospital,Department of Medical Biochemistry
[6] University of Sydney,Unit of Family Practice
[7] Flinders Medical Centre,Department of Cardiology
[8] Central Finland Central Hospital,Department of Molecular and Clinical Genetics
[9] Nelson Hospital,undefined
[10] Royal Prince Alfred Hospital,undefined
来源：
Diabetologia | 2013年 / 56卷
关键词：
Amputation; Bilirubin; Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study; Peripheral arterial disease; Type 2 diabetes mellitus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：724 / 736
页数：12
相关论文
共 50 条
  • [31] The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study
    Kwok-Leung Ong
    Andrzej S. Januszewski
    Rachel O’Connell
    Alicia J. Jenkins
    Aimin Xu
    David R. Sullivan
    Philip J. Barter
    Wei-Ting Hung
    Russell S. Scott
    Marja-Riitta Taskinen
    Anthony C. Keech
    Kerry-Anne Rye
    Diabetologia, 2015, 58 : 464 - 473
  • [32] The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study
    Ong, Kwok-Leung
    Januszewski, Andrzej S.
    O'Connell, Rachel
    Jenkins, Alicia J.
    Xu, Aimin
    Sullivan, David R.
    Barter, Philip J.
    Hung, Wei-Ting
    Scott, Russell S.
    Taskinen, Marja-Riitta
    Keech, Anthony C.
    Rye, Kerry-Anne
    DIABETOLOGIA, 2015, 58 (03) : 464 - 473
  • [33] The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-study
    Ong, Kwok-Leung
    Wu, Liang
    Januszewski, Andrzej S.
    O'Connell, Rachel
    Xu, Aimin
    Scott, Russell S.
    Sullivan, David R.
    Rye, Kerry-Anne
    Li, Huating
    Ma, Ronald C. W.
    Li, Liping
    Gebski, Val
    Jenkins, Alicia J.
    Jia, Weiping
    Keech, Anthony C.
    DIABETES & VASCULAR DISEASE RESEARCH, 2021, 18 (04):
  • [34] Protection Against Nephropathy With Fenofibrate in Type 2 Diabetes Mellitus: The FIELD Study
    Keech, Anthony
    Drury, Paul
    Davis, Timothy M.
    Donoghoe, Mark
    Laakso, Markku
    Whiting, Malcolm
    Scott, Russell
    D'Emden, Michael C.
    CIRCULATION, 2009, 120 (18) : S419 - S420
  • [35] Association between serum total bilirubin levels and the risk of type 2 diabetes mellitus
    Yang, Min
    Ni, Changlin
    Chang, Baocheng
    Jiang, Zhenhuan
    Zhu, Yanjuan
    Tang, Yunzhao
    Li, Zhu
    Li, Chenguang
    Li, Bin
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 152 : 23 - 28
  • [36] Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]
    Cardiovascular Diabetology, 4
  • [37] Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]
    Scott, R.
    Best, J.
    Forder, P.
    Taskinen, M-R
    Simes, J.
    Barter, P.
    Keech, A.
    Barter, P.
    Best, J.
    Colman, P.
    d'Emden, M.
    Davis, T.
    Drury, P.
    Ehnholm, C.
    Glasziou, P.
    Hunt, D.
    Keech, A.
    Kesaniemi, Y. A.
    Laakso, M.
    Scott, R.
    Simes, R. J.
    Sullivan, D.
    Taskinen, M-R
    Whiting, M.
    Ansquer, J-C
    Fraitag, B.
    Anderson, N.
    Hankey, G.
    Hunt, D.
    Lehto, S.
    Mann, S.
    Romo, M.
    Li, L. P.
    Hennekens, C.
    MacMahon, S.
    Pocock, S.
    Tonkin, A.
    Wilhelmsen, L.
    Forder, P.
    Akauola, H.
    Alford, F.
    Barter, P.
    Beinart, I.
    Best, J.
    Bohra, S.
    Boyages, S.
    Colman, P.
    Connor, H.
    Darnell, D.
    Davis, T.
    CARDIOVASCULAR DIABETOLOGY, 2005, 4 (1)
  • [38] Clinical insights from the Fenofibrate Intervention and Event Lowering in Diabetes study: a community practice perspective
    Toth, P. P.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (06) : 903 - 911
  • [39] Lipid Lowering, Antiinflammatory, and Vasoprotective Effects of Fenofibrate in Patients With Type 2 Diabetes Mellitus
    Tkacheva, O. N.
    Sharashkina, N. V.
    Novikova, I. M.
    Torshkhoeva, Kh. M.
    KARDIOLOGIYA, 2010, 50 (05) : 36 - 41
  • [40] Serum PEDF levels in type 2 diabetes: correlations, predictive power for vascular events and increases by fenofibrate in the FIELD Study
    Jenkins, A.
    Januszewski, A.
    Calandro, D.
    Sullivan, D.
    Ma, J. -X.
    Best, J.
    O'Connell, R.
    Blankenburg, S.
    Simes, J.
    Scott, R.
    Whiting, M.
    Barter, P.
    Taskinen, M. -R.
    Keech, A.
    DIABETOLOGIA, 2014, 57 : S502 - S502
12345